The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects.
The newly recognised apolipoprotein (apo) AV gene (APOAV) has been linked to fasting plasma triglyceride (TG) concentrations with some polymorphisms associated with elevated fasting TGs. Since fasting plasma TGs are mainly determined by the hepatic production of TG-rich particles (very low density lipoprotein; VLDL), and fasting TGs are the major determinants of postprandial lipaemia, we have evaluated the effects of an APOAV polymorphism on postprandial triglyceridaemia, which is largely determined by the intestinal production and clearance of chylomicrons. For this purpose, diurnal capillary triglyceridaemia (reflecting postprandial lipaemia) was determined in a cohort of 88 healthy volunteers (48 males and 40 females) in relation with a -1131T>C variant in the promoter of APOAV. Thirteen of these subjects (7 males and 6 females) were carriers of the -1131C allele, which has been associated with higher fasting plasma TG levels. The carriers had higher fasting capillary TG concentrations, although plasma TGs were not significantly different from non-carriers in this cohort. Surprisingly, total diurnal triglyceridaemia calculated as the area under the capillary TG curve was similar in carriers compared to non-carriers but after correction for fasting capillary TG levels, incremental diurnal triglyceridaemia was significantly lower in carriers (1.74 (5.27) mmol/h/l) than in non-carriers (4.91 (4.90) mmol/h/l; p = 0.036). The same trends were found for both males and females when analysed separately. Since dietary intake, which is a major determinant of incremental diurnal triglyceridaemia, did not differ between the two groups, we believe that these differences are at least partly explained by the APOAV. In summary, the APOAV assessed by means of the -1131T>C variant seemed to have a paradoxical effect on postprandial lipaemia when compared to fasting TG levels.
Masana
Lluis
L
Unitat de Recerca de Lípids i Arteriosclerosi, Institut de Recerca en Ciències de la Salut, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Spain. lmm@fmcs.urv.es
Ribalta
Josep
J
Salazar
Juliana
J
Fernández-Ballart
Joan
J
Joven
Jorge
J
Cabezas
Manuel Castro
MC
D000328:Adult; D000072040:Apolipoprotein A-V; D001053:Apolipoproteins; D001054:Apolipoproteins A / Q000235:genetics*; D017931:DNA Primers / Q000737:chemistry; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008075:Lipoproteins, HDL; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D019518:Postprandial Period; D014280:Triglycerides / Q000097:blood*
C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001053:Apolipoproteins; D001054:Apolipoproteins A; D017931:DNA Primers; D008075:Lipoproteins, HDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides